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I mprovements in clinical results, technology, andclearances by the Food and Drug Administration of
several ventricular assist device (VAD) systems have
led to more widespread clinical applications, not only
of sophisticated pulsatile devices but also centrifugal
pumps and portable cardiopulmonary bypass systems
or extracorporeal membrane oxygenation (ECMO).
Most cardiac surgical centers in the United States now
have the capability to provide short-term mechanical
circulatory support with devices more advanced than
the intra-aortic balloon pump (IABP). This availability
Objective: Improving results with ventricular assist devices have led to their
wider clinical application. Centers can stabilize, support, and wean or trans-
fer patients to regional transplant centers.
Methods: Prospectively collected data were reviewed to evaluate the clinical
results of patients transferred to our institution while receiving advanced
mechanical circulatory support.
Results: Since 1993, 16 patients were accepted while receiving support with
either extracorporeal membrane oxygenation or a ventricular assist device.
The 10 male and 6 female patients ranged in age from 9 to 60 years (mean,
42.1 years). Thirteen had had cardiac surgical procedures, two had acute
myocardial infarctions, and one had myocarditis. The distance transported
ranged from 0.2 to 309 miles (mean, 132 miles). Twelve patients were trans-
ferred by ground, and 4 were transported by air. Seven patients were origi-
nally supported with extracorporeal membrane oxygenation, 6 with centrifu-
gal pumps, and 3 with ABIOMED ventricular assist devices (ABIOMED,
Inc, Danvers, Mass). Two patients had clinical complications during transfer,
and one had a cerebrovascular accident, recovered, was weaned, and sur-
vived. A second patient had hemodynamic deterioration. There were no tech-
nical complications associated with transport. Six patients were left on the
original support device; 3 of the 6 were weaned and survived, and 3 died dur-
ing support. The 10 remaining patients were switched to other ventricular
assist devices: 9 patients to Thoratec devices (Thoratec Laboratories,
Pleasanton, Calif) and 1 patient to a Novacor device (Baxter Healthcare
Corp, Novacor Division, Oakland, Calif). Six of the 10 patients underwent
transplantation and survived. Four patients died while being supported by the
devices. Nine patients were discharged, with 1 late death at 29 months. Eight
patients are alive 4 to 65 months after discharge.
Conclusions: These data suggest that patients receiving advanced support can
be moved between clinical centers with acceptable risks. Because 33% of the
survivors were weaned, transplantation is not required for survival. (J Thorac
Cardiovasc Surg 2000;119:1015-20)
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TRANSFER OF PATIENTS RECEIVING ADVANCED MECHANICAL CIRCULATORY SUPPORT
Lawrence R. McBride, MD
CARDIOPULMONARY SUPPORT AND PHYSIOLOGY
allows support to be initiated quickly at the communi-
ty level. Patients can then be supported until myocar-
dial recovery occurs or, if appropriate, referred to a
regional transplant center. In most cases it is under-
stood that the time necessary to locate a suitable donor
heart necessitates that the temporary device implanted
at the local center be switched to a longer term system
that can provide intermediate interval support. Some
community centers may transport a patient to the
regional center for weaning when stabilized because
larger institutions would have greater resources avail-
able and specific expertise in the field of mechanical
circulatory support.
Patients and methods
Prospectively collected parameters from our mechanical
circulatory support database were reviewed to identify
patients transferred from outside institutions, while being pri-
marily supported with mechanical circulatory support devices
(VADs or ECMO) other than IABPs. Data were collected by
cardiothoracic clinical nurses specifically trained and dedi-
cating 100% of their efforts to mechanical circulatory sup-
port. All patients were in cardiogenic shock receiving multi-
ple inotropic and antiarrhythmic drugs. They were intubated,
paralyzed, and sedated. Some patients had an IABP, as well
as VADs or ECMO.
Most patients were accepted from the referring center on the
basis of information exchanged during several telephone con-
versations. Only 2 patients were seen by the receiving center
before transfer from a neighboring pediatric hospital.
Candidates were excluded for transfer if they were actively
bleeding, severely hypoxic (PO2 < 50 mm Hg on 100% oxygen),
anuric, or receiving inadequate support as defined by an assist
device flow index of less than 2 L · m–2 · min–1, a mean arterial
blood pressure of less than 50 mm Hg, or refractory systemic
acidosis. Because patients were supported with either ECMO or
VADs, hemodynamic parameters, such as cardiac output and
cardiac chamber pressures, were not prime considerations in
determining transfer acceptability. Neurologic status was diffi-
cult to assess; however, all patients were thought to be in neu-
rologically intact condition before transfer. The logistics of
patient transportation were jointly arranged by the referring and
receiving centers. Air transport was accomplished by helicopter.
No fixed-wing aircraft were used.
After transport and stabilization, each patient was evaluat-
ed on the basis of cardiac history, major organ function, trans-
esophageal echocardiogram results, and device on-off data.
By means of these parameters, patients were divided into 2
groups. The first group was made up of patients who would
be left on the initial device. This included patients whose con-
dition was deteriorating despite all efforts, as well as patients
who were showing evidence of myocardial recovery. The sec-
ond group was made up of patients whose deterioration had
been halted and were thought to have irreversible cardiac
damage that would require cardiac transplantation for sur-
vival. This latter group was switched to longer term devices
(Thoratec; Thoratec Laboratories, Pleasanton, Calif; and
Novacor; Baxter Healthcare Corp, Novacor Division,
Oakland, Calif) that could support them until a donor heart
could be located. Patients who were switched to longer term
devices had their cardiac function evaluated serially after 2 to
3 weeks of stabilized support by means of echocardiograms,
device on-off data, and cardiac catheterization with angiogra-
phy in some cases.
The operative procedure for placement of the device was
similar for all patients who were switched to Thoratec or
Novacor devices. VAD implants were performed, using full
cardiopulmonary bypass in beating hearts with normothermia
and femoral-femoral or bicaval–ascending aortic cannulation.
Preoperative and intraoperative echocardiographic examina-
tions, intraoperative palpation of the intra-atrial septum, or
both was used to determine whether there was a patent fora-
men ovale. Cannulation for a right VAD was from the right
atrium or right ventricle to the pulmonary artery. For left
VADs, cannula was routed from the left ventricular apex to
the aorta. Technical descriptions and implantation procedures
for devices used have been previously reported.1-5
For patients who were switched, once cardiopulmonary
bypass was discontinued, heparin was fully reversed with
protamine. As soon as postoperative bleeding had stopped
and coagulation factors were normalizing, anticoagulation
was initiated with heparin at 10 U · kg–1 · h–1. This usually
occurred approximately 24 hours postoperatively. Twenty-
four hours later, heparin was increased to maintain the partial
thromboplastin time at 1.5 times that of the control. As soon
as possible, oral warfarin was started to maintain the pro-
thrombin international normalization ratio at 3.0. Once the
target level of warfarin (international normalization ratio of
2.5) was reached, heparin was discontinued. Aspirin, 325
mg/d, was started 7 days postoperatively if the platelet count
was greater than 100,000 mm3 and increasing. Patients left on
the original devices received continuous heparin infusions to
maintain the activated clotting times at 180 to 200 seconds.
Prophylactic antibiotics were administered preoperatively
and for a minimum of 3 days after VAD implantation.
Postoperative complications were defined as follows.
1. Bleeding. Chest tube drainage greater than 1500
mL/m2 of body surface area during the first 24 hours after
operation or the need to re-explore the previous sternotomy
for bleeding.
2. Infection. Need for intravenous antibiotic therapy.
3. Pulmonary. Mechanical ventilatory support for more than
7 days after device implantation or the need to be reintubated.
4. Neurologic. Identification of a cerebrovascular accident
by means of clinical findings, computed tomography, or post-
mortem examination.
5. Renal failure. Renal insufficiency necessitating dialysis.
6. Device malfunction. Mechanical malfunction of the
control console necessitating a change to a backup console or
malfunction of any other component of the device, such as
the blood sac, valve, or electronics.
Survival was defined as being able to be discharged to
home from the hospital.
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Data were analyzed with the StatView for Windows statis-
tical software package (version 4.53; Abacus Concepts, Inc,
Berkeley, Calif). Values are reported as the mean ± 1 SD.
Results
Between October 1993 and June 1999, 68 patients
were supported with VADs (n = 60) or ECMO (n = 8)
at Saint Louis University Hospital. Sixteen additional
patients were transferred to our institution while
receiving advanced mechanical circulatory support.
Age, sex, and diagnosis are shown in Table I. All
patients were receiving inotropic drugs at the time of
transfer, ranging from 1 to 3 (mean, 2.4 ± 0.6) drugs
per patient. Fifteen of the 16 patients were receiving
antiarrhythmic drugs, averaging 1.2 ± 0.4 drugs per
patient. Only 4 patients were receiving vasodilators.
The initial device inserted, time of transfer after initial
device insertion, distance transported, whether the
device was switched, and duration on the initial device
are shown in Table II. The distances transported ranged
from 0.2 miles (a neighboring pediatric hospital) to 309
miles (mean, 132 miles). Seven patients were original-
ly supported with ECMO, 6 with centrifugal pumps,
and 3 with ABIOMED VADs.
One patient (patient 5, 6%) had a cerebrovascular
accident during transport, recovered, was weaned, and
survived. The condition of an additional patient
(patient 14) deteriorated during transfer with a decrease
in ABIOMED flows (bleeding and right ventricular
dysfunction) resulting in hypotension and severe sys-
temic acidosis. No further clinical complications were
associated with transport. There were no significant
technical problems related to patient transfer.
Complications identified after transfer are listed in
Table III. Six patients were not switched from the orig-
inal device (Table II). Three of these 6 were weaned
from their initial devices and survived. Three patients
died while supported by the initial device (Table III).
Ten patients were switched to other VADs, of whom 6
underwent transplantation and survived. Four patients
did not ungergo transplantation and died while being
supported by assist devices after being switched. Nine
patients were discharged from the hospital. There was
1 late death attributed to cardiac arrhythmia at 29
months after transplantation. Length of hospitalization
ranged from 1 to 175 days (mean, 51.1 ± 12.6 days).
Hospitalization in nonsurvivors averaged 16.4 ± 20.8
days, with survivors averaging 78 ± 50.4 days of hos-
pitalization. The 5-year actuarial survival was 45%.
The 10 patients who were switched to longer term
devices were supported from 4.2 to 157 days. Four of
these 10 patients did not have their cardiac function
evaluated with the device off. The condition of 2
patients steadily deteriorated after placement of
Thoratec assist devices and they died 4 and 15 days
postoperatively. One was supported for 56 days while
in continuous ventricular tachycardia, and 1 patient had
a severe cerebrovascular accident early in her postoper-
ative course. The 6 remaining patients had their ven-
tricular function evaluated by means of the previously
described techniques. After the assist devices had been
off for 3 minutes, left ventricular ejection fractions
ranged from 10% to 30% (mean, 19%) with rapidly
increasing pulmonary artery wedge pressures and heart
rates. The 2 patients who underwent coronary angiog-
raphy both had patent bypass grafts that had been put
in place at the original operation.
Discussion
For decades, clinicians have worked toward design-
ing a simple and effective method of mechanically sup-
porting the circulation during periods of transport.
Initially, portable cardiopulmonary bypass units and
then IABPs were thought to be reasonable options.6-8
However, early cardiopulmonary bypass systems were
cumbersome and difficult to manage. Portable IABP
systems were efficient, but they had a limited effect in
supporting patients with severe cardiogenic shock.
Over the past 20 years, mechanical circulatory support
has made significant advances in several areas. Clinical
results in both the recovery and bridge-to-transplant
groups appear to be improving. The commercialization
of several devices have helped to remove the investiga-
tional stigma from assist devices and made them more
widely available. The Health Care Finance Adminis-
tration and some private insurers have signaled support
by providing reimbursement. Despite these advances,
most centers recognize the significant resources required
to initiate and maintain an active mechanical circulatory
support program. The additional necessity to have a
complementary cardiac transplant program tends to
regionalize circulatory support centers.
Devices, such as the ABIOMED VAD, centrifugal
pumps, and ECMO, allow local centers to support
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Table I. Patient characteristics
Age 9-60 y (mean, 42.1 y; median, 45 y)
Sex 10 male, 6 female
Diagnosis-procedure CABG = 8
MVR + CABG = 2
MVR + AVR = 2
AMI = 2
Myocarditis = 1
ROSS procedure = 1
CABG, Coronary artery bypass graft; MVR, mitral valve replacement; AVR,
aortic valve replacement; AMI, acute myocardial infarction.
patients who have refractory cardiogenic shock.
Despite the fact that centrifugal pumps and ECMO
have been available for some time, it is only recently
that patients supported with these devices would be
considered for transfer between institutions. It is some-
times the intent of the local center at the time of initial
device implantation to stabilize and then transfer the
patient to a larger regional center. This is especially true
if the patient is less than 65 years of age and has no
obvious contraindications to cardiac transplantation.
Other times it may be decided to care for the patient
locally, if there is hope that myocardial recovery will
occur within a few days. If recovery does not occur
within 3 to 4 days, then consideration may be given to
transferring the patient for continued support, weaning,
or transplantation.
For this initial experience, patient selection criteria
were relatively loose. If the patient was less than 65
years of age and there were no obvious contraindica-
tions to survival, then the patient was accepted. To opti-
mize the opportunity for survival, it was hoped that a
majority of the transferred patients would also meet the
criteria for cardiac transplantation. Our initial plan was
to gain experience and establish referral patterns by
accepting almost all candidates. Once experience was
gained, we would then become more selective on the
basis of criteria determined during our initial clinical
experience. However, the number of referrals has been
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Table II. Device and transfer data
Time of transfer Distance Duration on 
Patient Initial device (h after initial device) transported (miles) Device switched initial device (h)
1 ECMO 24 22.0 No 48
2 ECMO 20 174.0 No 42
3 ECMO 12 22.0 No 24
4 ECMO 57 309.0 Novacor-LVAD 73
5 MED/BIO-BVAD 74 115.0 Thoratec-LVAD 90
6 MED/BIO-BVAD 77 20.0 Thoratec-LVAD 88
7 MED/BIO-BVAD 16 309.0 No 38
8 MED/BIO-BVAD 128 20.0 Thoratec-BVAD 142
9 MED/BIO-BVAD 62 115.0 Thoratec-LVAD 72
10 ECMO 20 309.0 Thoratec-BVAD 28
11 ECMO 1 0.2 Thoratec-LVAD 3
12 ABIOMED-LVAD 12 212.0 No 20
13 ABIOMED-LVAD 24 212.0 Thoratec-LVAD 36
14 ABIOMED-LVAD 72 265.0 No 164
15 ECMO 8 15.0 Thoratec-LVAD 12
16 MED/BIO-BVAD 13 0.2 Thoratec-BVAD 16
LVAD, Left ventricular assist device; MED/BIO, Medtronic/Bio-Medicus; LVAD, left ventricular assist device; BVAD, biventricular assist device.
Table III. Complications and results
Patient Complications Outcome Cause of death
1 Renal and pulmonary Died on device Renal and pulmonary failure
2 Bleeding Weaned-survived
3 Renal and pulmonary Died on device Renal and pulmonary failure
4 Bleeding and infection Transplanted-survived
5 Bleeding and neurologic (CVA) Transplanted-survived Late death; arrhythmia
6 Bleeding Transplanted-survived
7 Infection Weaned-survived
8 Bleeding, infection, renal, and pulmonary Died on device MOF
9 Bleeding Transplanted-survived
10 Bleeding, pulmonary, and infection Died on device MOF
11 None Transplanted-survived
12 Pulmonary Weaned-survived
13 Neurologic Died on device CVA
14 Bleeding, pulmonary, and renal Died on device MOF
15 Bleeding and pulmonary Transplanted-survived
16 Bleeding, pulmonary, and neurologic Died on device Intracranial bleeding
CVA, Cerebrovascular accident; MOF, multiple organ failure.
relatively small, and it has been difficult to identify any
accurate predictors of mortality. Several warning fac-
tors for transfer, however, have surfaced. These include
parameters that would signal instability and jeopardize
hemodynamics during the period of transport. This cat-
egory includes active bleeding, inadequate device sup-
port (<2 L · m–2 · min–1), persistent hypotension (mean
arterial pressure < 50 mm Hg), unresponsive ventricu-
lar arrhythmias, and refractory metabolic acidosis.
Other factors that suggest irreversible organ dysfunc-
tion before transfer include severe hypoxia (PO2 < 50
mm Hg with a fraction of inspired oxygen of 100%),
anuria, and neurologic injury. All of the above-listed
parameters can be accurately measured and evaluated,
except neurologic injury. These patients were neuro-
logically intact before their acute decompensation.
From that point on, they were sedated and paralyzed.
Our philosophy has been to give the patient the edge
unless some clinical factor suggests a major neurolog-
ic insult.
The patients described in this report were transferred
from a large geographic area where approximately 50
hospitals perform cardiac surgery and 5 centers per-
form cardiac transplantation. These 16 patients were
sent from 10 institutions and undoubtedly represent a
small percentage of the total number of patients receiv-
ing mechanical circulatory support in this area over this
6-year period. Three patients not included in this arti-
cle were initially referred for transfer. In these cases it
was decided that they would be better served at the
referring center: 1 patient was bleeding, 1 had acute
renal failure, and 1 patient was showing early myocar-
dial recovery. One of these 3 patients with renal failure
survived. Therefore these 19 patients represent the total
number referred to our institution while being support-
ed by either VADs or ECMO. Another 57 patients
receiving inotropic drugs and IABP support were trans-
ferred to our facility during the same time period for
heart transplant-VAD evaluation. Twelve of these 57
patients had VADs inserted (1 was weaned, 8 under-
went transplantation, and 3 died). The number of refer-
rals per year has remained fairly constant over this 6-
year period, despite the proliferation of VAD systems
into community hospitals.
We believe that the option of cardiac transplantation
is what stimulates transfer in this patient population.
Therefore a local center with an older patient (>65
years of age) or a patient with significant comorbidity
that would exclude him or her from cardiac transplan-
tation would probably not be referred. The oldest
patient in this group was 60 years of age, and a prelim-
inary evaluation of his medical history by telephone
failed to reveal any obvious contraindication to trans-
plantation. Patients older than 60 years of age would be
considered for transfer with the hope that they could be
weaned. Clinical experience, however, has identified
age greater than 70 years as a predictor of mortality.9
We have been hesitant to bridge patients on our trans-
plant list older than 60 years.
Thirteen of the 16 patients were transferred within 24
hours of cardiac surgery. This postcardiotomy cohort
was the largest subgroup for several reasons, including
the acute nature of their deterioration, as well as imme-
diate access to mechanical devices and personnel to
implant and manage them. Postcardiotomy patients are
especially unstable because of the frequency and sever-
ity of postoperative bleeding. Bleeding is a significant
impediment to transport, and our recommendation was
that all bleeding be controlled before initiating transfer.
In this small study the type of device implanted at the
original center did not influence survival. Four of the 7
patients transferred while supported by ECMO, 4 of the
6 patients transferred while supported by centrifugal
pumps, and 1 of the 3 patients transferred while sup-
ported by the ABIOMED VAD survived. Fortunately,
13 of the 16 patients were receiving biventricular sup-
port in the form of ECMO or biventricular assist
devices at the time of transfer. The use of biventricular
support during transfer reduces the problems associat-
ed with right ventricular failure and arrhythmias. At the
same time, the need for continued biventricular sup-
port, including ECMO (6 patients were switched from
biventricular support to left ventricular support after
transfer), was associated with nonsurvival. Five of the
7 nonsurvivors were receiving biventricular support at
the time of death, whereas only 2 of the 9 survivors
required biventricular support.
All 16 patients had acute cardiac events. None had a
history of congestive heart failure, and only 2 had pre-
vious myocardial infarctions. Therefore we considered
myocardial recovery as a possibility in all these cases.
Of the 6 patients left on the original devices, 3 showed
no evidence of myocardial recovery and died, whereas
3 were weaned within 48 hours of device insertion.
Four of the 10 patients who were switched to other
VADs had complications that precluded weaning or
transplantation and died while on support. The 6
remaining patients showed varying degrees of myocar-
dial recovery; however, none met our minimum
requirements for VAD removal. These include a left
ventricular ejection fraction of 35% to 40%, a left atri-
al or pulmonary artery wedge pressure of less than 20
mm Hg, and a mean systemic blood pressure of greater
than 65 mm Hg with the VAD off. Two of the postop-
erative patients undergoing coronary bypass showed
some cardiac recovery and had coronary angiography
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to evaluate the status of their bypass grafts. In both
patients the grafts were patent. This was a surprising
finding because these 2 patients had well-documented
(enzymes, electrocardiography, and biopsy) intraopera-
tive myocardial infarctions and very poor left ventricu-
lar function (left ventricular ejection fractions of 10%
and 16%) during on-off studies.
The overall survival of 56% was better than we
expected. Six of the 10 bridge-to-transplant patients
underwent transplantation and survived—a survival
similar to the overall survival of our bridge-to-transplant
population (70%). At the same time, 3 of the 6 patients
who were not switched to other devices were weaned
and survived. This 50% survival was better than the
30% survival we have been able to maintain in our in-
house myocardial recovery population. Of particular
interest are the 3 postcardiotomy patients who were
weaned from support and survived. This 23% survival
(3/13 postcardiotomy) is similar to the survival results
presented in a recent registry report.9 The 6 remaining
survivors underwent transplantation, which was an
option that was unavailable at the original center.
Previous reports have described interhospital trans-
port of patients receiving circulatory support with
ECMO, centrifugal assist pumps, and paracorporeal
VADs.10-12 Survival in the largest series was 50%.10
This survival is similar to ours and suggests that centers
should anticipate near 50% survival in patients who are
considered for transfer while receiving advanced
mechanical circulatory support. This survival will vary
on the basis of patient selection criteria, as well as the
level of communication between the transferring cen-
ters.
Fortunately, only 1 patient was found to have irre-
versible multiple organ failure at the time of arrival at
our institution. Her condition had deteriorated signifi-
cantly during transfer, which took longer than 5 hours,
and she eventually died while being supported by the
original device. All transfers were accomplished by
using conventional staff, which included physicians,
critical care nurses, perfusionists, and emergency med-
ical technicians. None of the personnel directly
involved in the transfers were specifically trained in cir-
culatory support or transport of such patients.
The transfer of a patient requiring ECMO or VAD
support is not so much a problem of technical safety but
rather whether the patient is hemodynamically stable to
survive several hours outside an intensive care unit
environment. For this reason, the total transfer time
should be kept as short as possible, probably less than
5 to 6 hours. There were no mechanical or device-relat-
ed complications associated with these transfers. Most
patients had severe ventricular arrhythmias and moder-
ate bleeding and were receiving multiple intravenous
medications. Proper cannulation techniques and antici-
pation of complications should reduce technical risks
significantly. A significant amount of blood-product
volume should be available during transport, as well as
emergency contingencies for the device being used.
Space considerations during transport may limit the
capability to carry backup battery power packs, hand
cranks, and control consoles.
This article suggests that by using current technology
and clinical techniques, patients can be effectively and
safely transferred between institutions while receiving
advanced mechanical circulatory support. These trans-
fers can be accomplished by using available staff and
transport.
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